- The P-III CheckMate -274 study involves assessing of Opdivo vs PBO in 709 patients in a ratio (1:1) with muscle-invasive urothelial cancer at a high risk of recurrence after radical surgery for up to 1yr.
- The study met its 1EPs of DFS in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% and showed a reduction in risk of relapse in the adjuvant settings, safety profile is consistent with previous studies in solid tumors
- The company will continue the study as planned to allow for future analyses of 2EPs, including OS and disease-specific survival. Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response
Click here to read full press release/ article | Ref: BMS | Image: The Social Medwork